238 related articles for article (PubMed ID: 38158477)
1. Systemic Therapy for Melanoma Brain and Leptomeningeal Metastases.
Sherman WJ; Romiti E; Michaelides L; Moniz-Garcia D; Chaichana KL; Quiñones-Hinojosa A; Porter AB
Curr Treat Options Oncol; 2023 Dec; 24(12):1962-1977. PubMed ID: 38158477
[TBL] [Abstract][Full Text] [Related]
2. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
[TBL] [Abstract][Full Text] [Related]
3. Mutational Status and Clinical Outcomes Following Systemic Therapy with or without Focal Radiation for Resected Melanoma Brain Metastases.
Vasudevan HN; Susko MS; Ma L; Nakamura JL; Raleigh DR; Boreta L; Fogh S; Theodosopoulos PV; McDermott MW; Tsai KK; Sneed PK; Braunstein SE
World Neurosurg; 2023 Feb; 170():e514-e519. PubMed ID: 36400359
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.
Ahmed KA; Abuodeh YA; Echevarria MI; Arrington JA; Stallworth DG; Hogue C; Naghavi AO; Kim S; Kim Y; Patel BG; Sarangkasiri S; Johnstone PA; Sahebjam S; Khushalani NI; Forsyth PA; Harrison LB; Yu M; Etame AB; Caudell JJ
Ann Oncol; 2016 Dec; 27(12):2288-2294. PubMed ID: 27637745
[TBL] [Abstract][Full Text] [Related]
5. Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases.
Trino E; Mantovani C; Badellino S; Ricardi U; Filippi AR
Expert Rev Anticancer Ther; 2017 Apr; 17(4):347-356. PubMed ID: 28277101
[TBL] [Abstract][Full Text] [Related]
6. Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies.
Long GV; Margolin KA
Am Soc Clin Oncol Educ Book; 2013; ():393-8. PubMed ID: 23714558
[TBL] [Abstract][Full Text] [Related]
7. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment.
Ly D; Bagshaw HP; Anker CJ; Tward JD; Grossmann KF; Jensen RL; Shrieve DC
J Neurosurg; 2015 Aug; 123(2):395-401. PubMed ID: 25768829
[TBL] [Abstract][Full Text] [Related]
8. Current Treatment of Melanoma Brain Metastasis.
Rishi A; Yu HM
Curr Treat Options Oncol; 2020 Apr; 21(6):45. PubMed ID: 32350685
[TBL] [Abstract][Full Text] [Related]
9. Molecular subtyping of brain metastases and implications for therapy.
Renfrow JJ; Lesser GJ
Curr Treat Options Oncol; 2013 Dec; 14(4):514-27. PubMed ID: 23907440
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
[TBL] [Abstract][Full Text] [Related]
11. Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects.
Diao K; Bian SX; Routman DM; Yu C; Kim PE; Wagle NA; Wong MK; Zada G; Chang EL
J Neurosurg; 2018 Dec; 129(6):1397-1406. PubMed ID: 29303446
[TBL] [Abstract][Full Text] [Related]
12. Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.
Wolf A; Zia S; Verma R; Pavlick A; Wilson M; Golfinos JG; Silverman JS; Kondziolka D
J Neurooncol; 2016 May; 127(3):607-15. PubMed ID: 26852222
[TBL] [Abstract][Full Text] [Related]
13. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases.
Xu Z; Lee CC; Ramesh A; Mueller AC; Schlesinger D; Cohen-Inbar O; Shih HH; Sheehan JP
J Neurosurg; 2017 Mar; 126(3):726-734. PubMed ID: 27203149
[TBL] [Abstract][Full Text] [Related]
14. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
Lau PKH; Feran B; Smith L; Lasocki A; Molania R; Smith K; Weppler A; Angel C; Kee D; Bhave P; Lee B; Young RJ; Iravani A; Yeang HA; Vergara IA; Kok D; Drummond K; Neeson PJ; Sheppard KE; Papenfuss T; Solomon BJ; Sandhu S; McArthur GA
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625515
[TBL] [Abstract][Full Text] [Related]
15. Severe Radiation Necrosis Refractory to Surgical Resection in Patients with Melanoma and Brain Metastases Managed with Ipilimumab/Nivolumab and Brain-Directed Stereotactic Radiation Therapy.
Shi DD; Arnaout O; Bi WL; Buchbinder EI; Cagney DN; Insco ML; Liu D; Schoenfeld JD; Aizer AA
World Neurosurg; 2020 Jul; 139():226-231. PubMed ID: 32330622
[TBL] [Abstract][Full Text] [Related]
16. On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases.
Gaudy-Marqueste C; Carron R; Delsanti C; Loundou A; Monestier S; Archier E; Richard MA; Regis J; Grob JJ
Ann Oncol; 2014 Oct; 25(10):2086-2091. PubMed ID: 25057167
[TBL] [Abstract][Full Text] [Related]
17. Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases.
Rauschenberg R; Bruns J; Brütting J; Daubner D; Lohaus F; Zimmer L; Forschner A; Zips D; Hassel JC; Berking C; Kaehler KC; Utikal J; Gutzmer R; Terheyden P; Meiss F; Rafei-Shamsabadi D; Kiecker F; Debus D; Dabrowski E; Arnold A; Garzarolli M; Kuske M; Beissert S; Löck S; Linn J; Troost EGC; Meier F
Eur J Cancer; 2019 Mar; 110():11-20. PubMed ID: 30739835
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases.
Dohm AE; Nakashima JY; Kalagotla H; Jiang SX; Tang JD; Bhandari M; Kim Y; Graham JA; Khushalani NI; Forsyth PA; Etame AB; Liu JK; Tran ND; Vogelbaum MA; Wuthrick EJ; Yu HM; Oliver DE; Ahmed KA
Eur J Cancer; 2023 Oct; 192():113287. PubMed ID: 37657227
[TBL] [Abstract][Full Text] [Related]
19. [Melanoma brain metastases : Treatment options].
Rauschenberg R; Tabatabai G; Troost EG; Garzarolli M; Beissert S; Meier F
Hautarzt; 2016 Jul; 67(7):536-43. PubMed ID: 27206449
[TBL] [Abstract][Full Text] [Related]
20. The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.
Sperduto PW; Jiang W; Brown PD; Braunstein S; Sneed P; Wattson DA; Shih HA; Bangdiwala A; Shanley R; Lockney NA; Beal K; Lou E; Amatruda T; Sperduto WA; Kirkpatrick JP; Yeh N; Gaspar LE; Molitoris JK; Masucci L; Roberge D; Yu J; Chiang V; Mehta M
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1069-1077. PubMed ID: 28721890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]